Northland Capmk Equities Analysts Decrease Earnings Estimates for MiMedx Group, Inc. (NASDAQ:MDXG)

MiMedx Group, Inc. (NASDAQ:MDXG) – Equities researchers at Northland Capmk cut their Q2 2024 EPS estimates for MiMedx Group in a research note issued to investors on Monday, July 1st. Northland Capmk analyst C. Byrnes now anticipates that the company will post earnings of $0.05 per share for the quarter, down from their prior forecast of $0.07. The consensus estimate for MiMedx Group’s current full-year earnings is $0.34 per share. Northland Capmk also issued estimates for MiMedx Group’s Q3 2024 earnings at $0.06 EPS.

Several other equities research analysts also recently commented on MDXG. StockNews.com downgraded shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a research note on Wednesday. HC Wainwright restated a “buy” rating and issued a $11.00 target price on shares of MiMedx Group in a research note on Wednesday, May 1st. Lake Street Capital assumed coverage on shares of MiMedx Group in a research note on Thursday, March 7th. They issued a “buy” rating and a $12.00 target price on the stock. Finally, Cantor Fitzgerald began coverage on shares of MiMedx Group in a research note on Tuesday. They issued an “overweight” rating and a $11.00 target price on the stock. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $12.00.

MiMedx Group Stock Up 0.6 %

Shares of NASDAQ:MDXG opened at $6.82 on Tuesday. MiMedx Group has a 52 week low of $5.57 and a 52 week high of $9.27. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.71 and a current ratio of 3.29. The company’s fifty day moving average is $7.17 and its 200-day moving average is $7.62. The company has a market capitalization of $1.01 billion, a PE ratio of 15.50 and a beta of 1.99.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings results on Tuesday, April 30th. The company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of $0.04 by $0.03. MiMedx Group had a net margin of 18.63% and a return on equity of 39.42%. The firm had revenue of $84.71 million for the quarter, compared to the consensus estimate of $79.36 million.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. AJOVista LLC bought a new stake in MiMedx Group during the 4th quarter worth about $25,000. Headlands Technologies LLC bought a new stake in MiMedx Group during the 1st quarter worth about $27,000. Entropy Technologies LP bought a new stake in MiMedx Group during the 1st quarter worth about $99,000. Loudon Investment Management LLC bought a new stake in MiMedx Group during the 4th quarter worth about $105,000. Finally, KMG Fiduciary Partners LLC bought a new stake in shares of MiMedx Group in the 4th quarter valued at about $105,000. 79.15% of the stock is owned by institutional investors.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.